AbbVie (NYSE:ABBV) Price Target Raised to $215.00 at BMO Capital Markets
AbbVie (NYSE:ABBV – Get Free Report) had its price objective lifted by equities research analysts at BMO Capital Markets from ...
Guggenheim Raises AbbVie (NYSE:ABBV) Price Target to $214.00
AbbVie (NYSE:ABBV – Get Free Report) had its price target upped by stock analysts at Guggenheim from $212.00 to $214.00 in a ...
2minutemedicine.com20h
Fecal Microbiota, live-jslm may be an effective means of preventing Clostridiodes difficile infections in patients with inflammatory bowel disease
The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection ...
The Armenian Reporter1h
AbbVie Inc. (NYSE:ABBV) Shares Acquired by Tanager Wealth Management LLP
Tanager Wealth Management LLP increased its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 20.5% in the 4th quarter, ...